NCT05351047 - A Study to Assess Safety, Tolerability, PK and PD of AZD2373 in Healthy Male Participants of Sub-Saharan West African Ancestry | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 4, 2022

Primary Completion Date

July 6, 2023

Study Completion Date

July 6, 2023

Conditions

Healthy Volunteers

Interventions

DRUG

AZD2373 subcutaneous injection

Randomized subjects will receive multiple ascending dose of AZD2373 by SC injection (dose 1, dose 2, dose 3, dose 4, dose 5).

DRUG

Placebo

Randomized subjects will receive a multiple ascending dose of placebo (saline solution) by SC injection.

Trial Locations (1)

Research Site, Brooklyn